We are international
• health professionals TEXT SIZE   
Bringing the Experts to You

ASH 2006 - Webcasts
previous     next      view all

Novel Agents - Relapsed/Refractory Myeloma
12.17.06   A Subset Study of Lenalidomide/Dexamethasone vd Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA

12.17.06   Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria

12.17.06   Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma
Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts USA

12.17.06   Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

12.17.06   Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

12.17.06   Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

12.17.06   Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC

12.17.06   Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
Edward A. Stadtmauer, MD
Hospital of the University of Pennsylvania
Philadelphia, PA

New Agents and Approaches
12.17.06   A Phase I Study of HCD122 (formerly CHIR1212), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma
William Bensinger, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

12.17.06   A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA

previous     next      view all